Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$65.34 USD
+0.54 (0.83%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 161 - 180 ( 304 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Importance of SVC Garners Further Support for VITALITY-ALS
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
''107 SMA Program Underway with Astellas; COPD Study to Follow
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOL Panel Highlight; "Drug Is Doing Something Completely Different"
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Numbers Are COSMIC; Nice Win for CYTK and AMGN; Target to $22
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Talk About Instant Gratification; Going COSMIC This Weekend
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q15 Results; Perspective is Key; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
A Nice COSMIC Event in the Galaxy; Bring on the Phase III; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Healthcare - Focusing on Value Creating Catalysts for Our CoverageThis report contains brief updates on the following: ADRO, AGTC, APHB, APTO, ARGS, BLRX, CFRX, CNCE, CYTK, CYTX, IMNP, PTN, STML, T.TST. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Prepping for COSMIC-HF Data and AMGN/CYTK Phase III Decision
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q15 Results; Tirasemtiv Phase III Execution Time; Omecamtiv Data Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Phase III VITALITY-ALS Is a Go; Anticipating 2H15 Catalysts Next
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J